PR Newswire

[Informing you about premier stocks before they hit Wall Street]

[ Business | US Market | Industry | IPO | S&P | International | PRNews | BizWire | Finance Home ]

Wednesday January 14, 9:29 am Eastern Time

Company Press Release

SOURCE: Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. Expands Clinical Trials

FORT LAUDERDALE, Fla., Jan. 14 /PRNewswire/ -- Imaging Diagnostic Systems, Inc. (OTC Bulletin Board: IMDS - news) announced today that the FDA has granted approval (letter dated Dec. 17, 1997) to include specific studies on augmented breasts as part of an extensive in-house study of the CT Laser Mammography (CTLM(R)) device for breast imaging. This testing is designed to develop diagnostic criteria for CTLM images.

A prominent university medical center has agreed to participate with Imaging Diagnostic Systems, Inc. to expand the first-phase clinical study to prepare for acquiring data that will be part of the final pre-market application (PMA).

Immediately thereafter, expanded clinical trials will commence in hospitals in Miami, Chicago, Los Angeles, Boston, and New York. At the conclusion of these studies the PMA data will be submitted to the FDA.

Imaging Diagnostic Systems, Inc., is developing the first patented laser- based system for detecting breast abnormalities which requires no breast compression or use of radiation. The CTLM produces three-dimensional cross- sectional images of the breast in a non-invasive procedure known as Computed Tomography Laser Mammography.

SOURCE: Imaging Diagnostic Systems, Inc.

More Quotes and News:Imaging Diagnostic Systems Inc (OTC BB:IMDS - news)
Related News Categories: medical/pharmaceutical

[ Yahoo! ]
Copyright © 1998 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
See our Important Disclaimers and Legal Information.
Questions or Comments?